GlaxoSmithKline will pay 400 million euros to Curevac, a German biopharmaceutical company, and may pay up to 1.05 billion euros in the future. The two companies will carry out a reorganization cooperation.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.